<code id='D64101193E'></code><style id='D64101193E'></style>
    • <acronym id='D64101193E'></acronym>
      <center id='D64101193E'><center id='D64101193E'><tfoot id='D64101193E'></tfoot></center><abbr id='D64101193E'><dir id='D64101193E'><tfoot id='D64101193E'></tfoot><noframes id='D64101193E'>

    • <optgroup id='D64101193E'><strike id='D64101193E'><sup id='D64101193E'></sup></strike><code id='D64101193E'></code></optgroup>
        1. <b id='D64101193E'><label id='D64101193E'><select id='D64101193E'><dt id='D64101193E'><span id='D64101193E'></span></dt></select></label></b><u id='D64101193E'></u>
          <i id='D64101193E'><strike id='D64101193E'><tt id='D64101193E'><pre id='D64101193E'></pre></tt></strike></i>

          focus

          focus

          author:Wikipedia    Page View:2274
          Boston Scientific headquarters -- Health coverage from STAT
          Boston Scientific is growing its urology portfolio with the Axonics acquisition. Steven Senne/AP

          Boston Scientific said it will buy Axonics, a device company treating urinary and bowel disorders, on Monday. The deal is worth $3.7 billion.

          It’s the first billion-dollar medical device deal of 2024 — a rare occurrence in 2023, which saw just a handful of medtech acquisitions reaching the billion threshold. Boston Scientific said it expects to close the deal in the first half of this year. Axonics’ stock increased by 20% in light of the news; Boston Scientific’s dropped slightly.

          advertisement

          Boston Scientific has acquired companies across all medtech sectors in the past year. The device maker bought Apollo Endosurgery, a company selling surgical tools to combat obesity, for $615 million in 2023. In September of 2023, Boston Scientific bought pain relief company Relievant for $850 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more
          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more
          After affirmative action ruling, medical educators look to 'holistic review'
          After affirmative action ruling, medical educators look to 'holistic review'

          AnnaMoneymaker/GettyImagesAfterhavingadaytoreadthroughtheSupremeCourt’sdecisiononaffirmativeaction,s

          read more

          Duchenne breakthrough therapy leaves behind pioneering families

          DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio